Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Winston

Showing results (261-270 of 373) with videos related to

Pageof 38
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2018
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell TransplantationFrancisco M Marty, Drew J Winston, Roy F Chemaly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patientsD J Winston, H M Lazarus, R A Beveridge, et al.
The Journal of Infectious Diseases|August 3, 2013
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adultsKathleen M Mullane, Drew J Winston, Michael S Wertheim, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 6, 2012
Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trialD J Winston, F Saliba, E Blumberg, et al.
American Journal of Human Genetics|February 17, 2001
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studiesC M Eng, M Banikazemi, R E Gordon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 13, 2018
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell TransplantationKathleen M Mullane, Drew J Winston, Ajay Nooka, et al.
The Lancet. Infectious Diseases|March 19, 2011
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trialFrancisco M Marty, Per Ljungman, Genovefa A Papanicolaou, et al.
International Journal of Environmental Research and Public Health|August 9, 2017
Estimated Maternal Pesticide Exposure from Drinking Water and Heart Defects in OffspringJihye Kim, Michael D Swartz, Peter H Langlois, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 21, 2020
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT StudyRoy F Chemaly, Lynn El Haddad, Drew J Winston, et al.
Open Forum Infectious Diseases|August 28, 2023
Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell TransplantElla J Ariza-Heredia, Drew J Winston, Scott D Rowley, et al.
Pageof 38

Showing results (261-270 of 373) with videos related to

Sort By:
Pageof 38
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 8, 2018
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell TransplantationFrancisco M Marty, Drew J Winston, Roy F Chemaly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2001
Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patientsD J Winston, H M Lazarus, R A Beveridge, et al.
The Journal of Infectious Diseases|August 3, 2013
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adultsKathleen M Mullane, Drew J Winston, Michael S Wertheim, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 6, 2012
Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trialD J Winston, F Saliba, E Blumberg, et al.
American Journal of Human Genetics|February 17, 2001
A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studiesC M Eng, M Banikazemi, R E Gordon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 13, 2018
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell TransplantationKathleen M Mullane, Drew J Winston, Ajay Nooka, et al.
The Lancet. Infectious Diseases|March 19, 2011
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trialFrancisco M Marty, Per Ljungman, Genovefa A Papanicolaou, et al.
International Journal of Environmental Research and Public Health|August 9, 2017
Estimated Maternal Pesticide Exposure from Drinking Water and Heart Defects in OffspringJihye Kim, Michael D Swartz, Peter H Langlois, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 21, 2020
Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT StudyRoy F Chemaly, Lynn El Haddad, Drew J Winston, et al.
Open Forum Infectious Diseases|August 28, 2023
Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell TransplantElla J Ariza-Heredia, Drew J Winston, Scott D Rowley, et al.
Pageof 38